Zum Hauptinhalt springen
ProhibitedOfficial guidanceCAOriginal is EnglishImport aus amtlicher Quelle geprüft

Dextromethorphan and its salts

Canada Hotlist: Dextromethorphan and its salts

Health Canada lists this ingredient as prohibited for use in cosmetic products.

Regulatorische Entscheidung und vollständige Bedingungen

Status
Prohibited
Rechtsrolle
Official guidance
Regulatorische Zusammenfassung
Health Canada lists this ingredient as prohibited for use in cosmetic products.
Bedingungen und Beschränkungen
A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. Öffnen Sie die zitierte Quelle und wenden Sie die unten genannten marktweiten Anforderungen an.

Stoffidentität

Name in der amtlichen Quelle
Dextromethorphan and its salts
CAS
125-71-3
EC
Not supplied in this source row
Identitätszuordnung
standalone:cas_number

Marktübergreifende Übersicht zu dieser Identität

Exakte verknüpfte Einträge, die derzeit auf dieser Website vorhanden sind. Ein fehlender Markt bedeutet, dass kein exakter Treffer importiert wurde, nicht dass der Stoff verwendet werden darf.

10 Marktdatensätze
Chemische 2D-Struktur aus PubChem für CAS 125-71-3
CAS 125-71-3PubChem CID 5360696

Verifizierte Chemie für CAS 125-71-3

Dextromethorphan

Dextromethorphan is a 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough. It has a role as a oneirogen, a xenobiotic, a prodrug, a neurotoxin, an antitussive, a NMDA receptor antagonist and an environmental contaminant. It is functionally related to a dextrorphan. It is an enantiomer of a levomethorphan. — ChEBI

IUPAC-Name
(1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
Summenformel
C18H25NO
Molekulargewicht
271.4 g/mol
Exakte Masse
271.193614421 Da
Monoisotopische Masse
271.193614421 Da
XLogP3
3,4
Topologische polare Oberfläche
12,5 Ų
Molekulare Komplexität
370,0
Formale Ladung
0
Wasserstoffbrücken-Donoren
0
Wasserstoffbrücken-Akzeptoren
2
Drehbare Bindungen
1
Schweratome
20
Kovalente Einheiten
1

An PubChem gemeldete Namen und Synonyme

d-Methorphandelta-MethorphanDextromorphanDextromethorfanDextrometorfanoDextromethorphaneAlbutussinDestrometerfano
16 weitere gemeldete Namen
DextromethorphanumBA 2666Balminil DM(+)-Dextromethorphan3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinanMorphinan, 3-methoxy-17-methyl-, (9alpha,13alpha,14alpha)-DXM [Antitussive]BA-26667355X3ROTSCHEBI:4470(+)-3-Methoxy-N-methylmorphinonNSC-751452DXM (Antitussive)(+)-cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren(+)-3-methoxy-17-methyl-9alpha,13alpha,14alpha-morphinanRoboTablets
Kennungen in externen Datenbanken
Erweiterte Strukturstatistik
Definierte Atom-Stereozentren
3
Nicht definierte Atom-Stereozentren
0
Definierte Bindungs-Stereozentren
0
Nicht definierte Bindungs-Stereozentren
0
3D-Pharmakophormerkmale
6
3D-Ringe
4
3D-Hydrophobe
0
3D-Akzeptormerkmale
1
3D-Donormerkmale
0
3D-Anionenzentren
0
3D-Kationenzentren
1
3D-Konformere
2
Effektive 3D-Rotoren
2,6
Maschinenlesbare Strukturkennungen
SMILES
CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
InChI
InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1
InChIKey
MKXZASYAUGDDCJ-NJAFHUGGSA-N

Belege aus weiteren wissenschaftlichen Datenbanken

NIH PubChem PUG-View
Exakter Kennungstreffer5360696

Attributed physical-property, hazard, environmental and use annotations.

  • Note: This chemical does not meet GHS hazard criteria for 46.8% (36 of 77) of reports. Quelle: European Chemicals Agency (ECHA)
  • Signal: Danger Quelle: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H301 (51.9%): Toxic if swallowed [Danger Acute toxicity, oral] Quelle: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement) Quelle: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 77 reports by companies from 4 notifications to the ECHA C&L Inventory.; Reported as not meeting GHS hazard criteria per 36 of 77 reports by companies.; There are 3 notifications provided by 41 of 77 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Quelle: European Chemicals Agency (ECHA)
  • Toxicity Summary: IDENTIFICATION AND USE: Dextromethorphan is a white odorless solid crystal or powder. It is an opium alkaloid derivative, which is found in cough and cold preparations. HUMAN STUDIES: Dextromethorphan is a drug of abuse. The main risks associated with dextromethorphan are ataxia, central nervous system (CNS) stimulation, dizziness, lethargy and psychotic behavior. Less frequently with large doses seizures and respiratory depression can occur. Nausea, vomiting, constipation and tachycardia may also occur. CNS effects include ataxia, drowsiness, vertigo and rarely coma. CNS stimulation may be observed. Restlessness, increased muscle tone with body rigidity have been reported. With extremely large ingestions respiratory depression can occur. Gastrointestinal effects include nausea, vomiting, constipation and dry mouth. Urinary retention may be seen. Dextromethorphan abuse has been described and produces euphoria, CNS stimulation, visual and/or auditory hallucinations. Dextromethorphan hydrobromide is the drug form, thus the possibility of bromide poisoning should be considered in the long term abuser. Dextromethorphan enhances serotonin activity by inhibiting the reuptake of serotonin Quelle: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: Signs and Symptoms of Overdose; One significant concern regarding dextromethorphan toxicity is its OTC misuse, which has steadily increased since the early 2000s. This misuse is referred to by slang terms such as "going pharming," "robotripping," and "dexing." In 2006, three specific OTC product formulations accounted for 66% of reported dextromethorphan misuse cases in the United States, with Coricidin HBP Cough & Cold Tablets and Robitussin products being prominent. A life-threatening toxicity associated with dextromethorphan abuse is serotonin syndrome, resulting from its serotonin reuptake inhibition properties. When combined with SSRIs or MAOIs, the risk of serotonin syndrome increases significantly. Symptoms include agitation, confusion, dilated pupils, headache, tachycardia, hypotension, high fever, seizures, irregular heartbeat, and may progress to unconsciousness.; Despite the rise in misuse, public health efforts and legislative actions restricting the sale of dextromethorphan-containing products to minors have helped stabilize or reduce abuse rates in recent years. However, continued vigilance is essential to prevent misuse and associated toxicities, given dextromethorph Quelle: StatPearls
  • Toxicity Summary: Dextromethorphan is an opioid-like drug that binds to and acts as antagonist to the NMDA glutamatergic receptor, it is an agonist to the opioid sigma 1 and sigma 2 receptors, it is also an alpha3/beta4 nicotinic receptor antagonist and targets the serotonin reuptake pump. Dextromethorphan is rapidly absorbed from the gastrointestinal tract, where it enters the bloodstream and crosses the blood-brain barrier. The first-pass through the hepatic portal vein results in some of the drug being metabolized into an active metabolite of dextromethorphan, dextrorphan, the 3-hydroxy derivative of dextromethorphan. Quelle: Toxin and Toxin Target Database (T3DB)
  • Environmental Bioconcentration: The estimated pKa of dextromethorphan is 9.8(1), indicating that dextromethorphan will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, bioconcentration in fish is not expected to be an important fate process(SRC). Quelle: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 23,000(SRC), determined from a structure estimation method(2), indicates that dextromethorphan is expected to be immobile in soil(SRC). The estimated pKa of dextromethorphan is 9.8(3), indicating that this compound will exist almost entirely in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the cation from moist soil is not expected because cations do not volatilize(SRC). Dextromethorphan is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.0X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2017). Quelle: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 23,000(SRC), determined from a structure estimation method(2), indicates that dextromethorphan is expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 9.8(3) indicates dextromethorphan will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces and bioconcentration in aquatic organisms are not expected to be an important fate processes(SRC). Dextromethorphan is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(4). Biodegradation data in water were not available(SRC, 2017). Quelle: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), dextromethorphan, which has an estimated vapor pressure of 1.0X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase dextromethorphan is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 3.3 hours(SRC), calculated from its rate constant of 1.2X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(2). Particulate-phase dextromethorphan may be removed from the air by wet or dry deposition(SRC). Dextromethorphan contains chromophores that absorb at wavelengths >290 nm(3) and, therefore, is expected to be susceptible to direct photolysis by sunlight(SRC). Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: Antitussive Agents; Excitatory Amino Acid Antagonists Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: Probe to determine cytochrome 450 phenotype Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: Dextromethorphan (DXM) is an over-the-counter (OTC) cough suppressant commonly found in cold medications. DXM is often abused in high doses by adolescents to generate euphoria and visual and auditory hallucinations. Illicit use of DXM is referred to on the street as "Robo-tripping" or "skittling." These terms are derived from the most commonly abused products, Robitussin and Coricidin. Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg; approx.) in Germany (2009): >1000; Use (kg) in USA (2002): 38000; Consumption (g per capita; approx.) in Germany (2009): 0.0122; Consumption (g per capita) in the USA (2002): 0.135; Excretion rate: 0.25; Calculated removal (%): 45.3 Quelle: NORMAN Suspect List Exchange
  • Uses: The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (as commonly accompanies the common cold), as well as those resulting from inhaled irritants. In addition, a combination of dextromethorphan and quinidine has been shown to alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis. Quelle: Toxin and Toxin Target Database (T3DB)

Zugeordnet durch: Existing checksum-valid CAS to unique PubChem CID match. Abgerufen: 2026-08-31. Quelleneintrag öffnen

Wissenschaftliche Klassifizierungen und Gefahrenannotationen liefern Kontext und ersetzen nicht die oben gezeigte marktspezifische regulatorische Entscheidung.

Weitere Quellenabdeckung und Trefferstatus
QuelleErgebnisGeprüft
NIH PubChem PUG-ViewExakter Treffer2026-08-31

Ein erfasster Nicht-Treffer ist ein nützlicher Beleg dafür, dass die Quelle geprüft wurde; er ist keine Behauptung, dass der Stoff anderswo nicht existiert.

Am 2026-08-31 von NIH PubChem durch prüfsummengültigen CAS-Abgleich abgerufen. Chemische Eigenschaften ersetzen nicht die regulatorische Entscheidung auf dieser Seite.

Amtliche Quelle und Herkunft

Registrierte Quelle
Health Canada Cosmetic Ingredient Hotlist
Quellenverweis
Hotlist prohibited entry 188
Eintrags-ID der Quelle
prohibited:188
Quellenversion
Health Canada Hotlist 2025-08-13
Quellsprache
English
Übersetzungsstatus
Original is English
Quelle aktualisiert
2025-08-13
Stand geprüft
2026-08-30 04:07 UTC
Validierungsmethode
strict HTML tables t1=490 and t2=90
SHA-256
8b52ff573d08373ee90121f6a701b3607e4a3d6fc748a7d56171eb53510af91a

Hinweise zum registrierten Datensatz

Datensatzabdeckung
Administrative prohibitions, restrictions, conditions and warning requirements
Hinweis zur Behörde
Official Health Canada compliance indicator; not a complete safety clearance

Wie dieser Eintrag in den Marktdatensatz passt

580
aktuelle Einträge für Canada
490
Einträge mit dem Status Prohibited
580
Einträge aus dieser Quellenversion
516
Markteinträge mit CAS-Identität

Statusverteilung

Bedingungstext ist bei 172 von 580 aktuellen Einträgen vorhanden. Ein leeres Bedingungsfeld wird entsprechend der oben genannten Eintragsart interpretiert; es wird niemals in die Aussage einer uneingeschränkten Verwendung umgedeutet.

Canada Marktkontext

Complete Hotlist snapshot

Abdeckungsversion: Health Canada Cosmetic Ingredient Hotlist, 13 August 2025

All prohibited and restricted Hotlist entries, including conditions and warning requirements published in the official list.

Verifizierungs-Checkliste

  1. Search English/French names and CAS identifiers.
  2. Apply every restriction, concentration and label warning.
  3. Check Food and Drugs Act/Cosmetic Regulations requirements.
  4. Recheck the current Hotlist before notification or sale.

Amtliche Marktquellen

Verifizierungsablauf und Vollständigkeit des Eintrags

Bevor Sie dieses Ergebnis für eine Compliance-Entscheidung verwenden

  1. Bestätigen Sie, dass „Dextromethorphan and its salts“ und jede CAS-/EC-Kennung sich auf das Material in Ihrer Lieferantenspezifikation beziehen.
  2. Search English/French names and CAS identifiers.
  3. Apply every restriction, concentration and label warning.
  4. Check Food and Drugs Act/Cosmetic Regulations requirements.
  5. Recheck the current Hotlist before notification or sale.
  6. Dokumentieren Sie die Quellenversion und prüfen Sie die Behörde vor Herstellung, Notifizierung oder Inverkehrbringen erneut.

In diesem Eintrag verfügbare Felder

  • Amtlicher StoffnameVerfügbar
  • CASVerfügbar
  • ECNicht angegeben
  • Gesonderter BedingungstextIn der Quellzeile nicht vorhanden
  • Datum des InkrafttretensNicht angegeben
  • Snapshot-Hash und MethodeVerfügbar

Fragen, die diese Seite beantwortet

This official record identifies the substance as prohibited for cosmetic use in the stated market scope. Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. The Hotlist is an administrative compliance tool, not an exhaustive safety approval list.

Der Eintrag zitiert Hotlist prohibited entry 188, Quellenversion Health Canada Hotlist 2025-08-13. Die amtliche Quelle öffnen.

Nein. CAS hilft bei der Klärung der Identität, aber Rechtsordnungen können denselben Stoff unterschiedlich einstufen und unterschiedliche Produktbereiche, Grenzwerte, Warnhinweise und Übergangsfristen anwenden.

Dauerhafte Zitierweise

Dextromethorphan and its salts. Hotlist prohibited entry 188. Canada. Source version Health Canada Hotlist 2025-08-13. CosIng Checker regulatory record: https://cosingchecker.com/de/regulations/ca/records/188/

Zitieren Sie die Aufsichtsbehörde als rechtliche Autorität. Diese Seite ist ein strukturierter Belegindex und eine Verifizierungshilfe, kein Ersatz für den amtlichen Text oder eine fachkundige rechtliche Bewertung.

Auslegung und Grenzen für Canada

This official record identifies the substance as prohibited for cosmetic use in the stated market scope.

Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

Wie die Rechtsrolle auszulegen ist

The authority uses this source as compliance guidance; the underlying legislation remains controlling.

Belege auf dieser Seite

  • Erfasstes Ergebnis: Prohibited
  • Rechtsrolle: Official guidance
  • Quellenversion: Health Canada Hotlist 2025-08-13

Was es nicht beweist

The Hotlist is an administrative compliance tool, not an exhaustive safety approval list.

Weitere maßgebliche Stoffrecherche

Keine dieser Quellen hebt die oben genannte Marktentscheidung auf.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Diese Identität bei der Quelle recherchieren

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Diese Identität bei der Quelle recherchieren

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Diese Identität bei der Quelle recherchieren

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Diese Identität bei der Quelle recherchieren

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Diese Identität bei der Quelle recherchieren

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Diese Identität bei der Quelle recherchieren

US EPA CompTox CTX APIs

Für den Import ist ein API-Schlüssel erforderlich

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Diese Identität bei der Quelle recherchieren